According to a recent LinkedIn post from Tubulis, the company is scheduled to participate in the 5th Novel Conjugate Summit 2026 in Boston from March 17–19, focusing on the future of targeted conjugate therapeutics. The post highlights that Tubulis’ Vice President of Chemistry and Early Discovery, Marc-André Kasper, is expected to co-lead a workshop with an AstraZeneca representative on next‑generation linker and conjugation strategies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also notes that Kasper plans to present how Tubulis’ conjugation platforms and linker technologies may enable stable, high‑performing degrader‑antibody conjugates. For investors, this visibility at a specialized industry summit and collaboration in a workshop alongside AstraZeneca could signal growing recognition of Tubulis’ technology and potential partnering opportunities in the antibody‑drug conjugate and targeted therapeutics space.
Such conference participation may support Tubulis’ positioning within the competitive biopharma innovation landscape, where differentiation in linker and conjugation chemistry is viewed as a key value driver. While the post does not reference financial metrics, regulatory milestones, or specific deals, increased scientific exposure and networking at this event could contribute indirectly to Tubulis’ business development pipeline and long‑term funding prospects.